Compass Therapeutics (CMPX) Equity Average (2023 - 2025)
Historic Equity Average for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $151.4 million.
- Compass Therapeutics' Equity Average rose 643.86% to $151.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.4 million, marking a year-over-year increase of 643.86%. This contributed to the annual value of $136.9 million for FY2024, which is N/A changed from last year.
- Latest data reveals that Compass Therapeutics reported Equity Average of $151.4 million as of Q3 2025, which was up 643.86% from $101.7 million recorded in Q2 2025.
- Over the past 5 years, Compass Therapeutics' Equity Average peaked at $171.8 million during Q2 2023, and registered a low of $101.7 million during Q2 2025.
- Its 3-year average for Equity Average is $144.0 million, with a median of $151.5 million in 2024.
- The largest annual percentage gain for Compass Therapeutics' Equity Average in the last 5 years was 643.86% (2025), contrasted with its biggest fall of 3287.92% (2025).
- Quarter analysis of 3 years shows Compass Therapeutics' Equity Average stood at $154.3 million in 2023, then dropped by 14.57% to $131.8 million in 2024, then increased by 14.87% to $151.4 million in 2025.
- Its Equity Average was $151.4 million in Q3 2025, compared to $101.7 million in Q2 2025 and $117.8 million in Q1 2025.